Clene (NASDAQ: CLNN) Reports Statistically Significant Long-Term Improvements for VISIONARY-MS Participants

Investor Brand Network
Tuesday, February 6, 2024 at 3:25pm UTC
  • Clene recently reported new results from the open-label, long-term extension (“LTE”) of the VISIONARY-MS trial, involving participants with stable relapsing Multiple Sclerosis (“MS”) through week 144 (over 2.75 years) after the initial randomization
  • Results from the 48-week double-blind period showed statistically significant improvements in vision (primary endpoint), as well as a combined improvement in cognition, walking speed, upper extremity function, and vision (secondary endpoint) with CNM-Au8 treatment, with further significant improvements in both vision and cognition extending throughout the 96-week LTE
  • One of the trial’s key clinical advisors hailed the results as robust and consistent, describing the observed long-term clinical improvements as unprecedented
  • Data from both the double-blind trial period and the LTE build a strong case for pursuing CNM-Au8(R) in upcoming Phase 3 studies, said Dr. Benjamin Greenberg, Head of Medicine at Clene

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently reported new results from the open-label long-term extension (“LTE”) of the VISIONARY-MS trial ( This was a double-blind, placebo-controlled Phase 2 clinical trial comprised of participants with chronic optic neuropathy associated with stable relapsing Multiple Sclerosis (“RMS”).

About Multiple Sclerosis

RMS is a disease of the central nervous system in which the body’s own immune system attacks myelin in the brain (the protective sheath that covers and protects nerve fibers). These attacks disrupt communication between the brain and the rest of the…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

The latest news and updates relating to CLNN are available in the company’s newsroom at

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
310.299.1717 Office